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Abstract
Background: Neuroblastoma (NB) is the second most common solid malignancy of childhood that usually
undergoes rapid progression with a poor prognosis upon metastasis. The Src-family tyrosine kinases (SFKs) are a
group of proteins involved in cancer development and invasiveness that seem to play an important role in the NB
carcinogenesis.
Methods: To determine cell proliferation, the growth rate was evaluated by both MTT test and cells counted.
Analysis of DNA content was performed for the evaluation of the cell cycle and apoptosis. To characterize the
mechanisms underlying the antiproliferative effects induced by SI 34, a novel pyrazolo-pyrimidine derivative
provided with Src inhibitory activity, the involvement of some cellular pathways that are important for cell
proliferation and survival was investigated by western blot assays. In particular, the contribution of cyclins, Src and
ERK were examined. Finally, experiments of cell adhesion and invasiveness were performed.
Results: Treatment of SH-SY5Y human NB cells and CHP100 human neuroepithelioma (NE) cultures with three
novel pyrazolo[3,4-d]pyrimidine derivatives, namely SI 34, SI 35 and SI 83, inhibits the cell proliferation in a time
and concentration-dependent manner. The maximal effect was obtained after 72 hours incubation with SI 34
10 μM. Fluorescence microscopy experiments, flow cytometry analysis and determination of caspase-3 activity by
fluorimetric assays showed that SI 34 induced SH-SY5Y apoptosis. Moreover, SI 34 determined cell cycle arrest at
the G0/G1 phase, paralleled by a decreased expression of cyclin D1. Furthermore, our data indicate that SI 34
reduces the SH-SY5Y cells adhesion and invasiveness. Evidence that SI 34 inhibits the Src and the ERK-
phosphorylation, suggests the mechanism through which it exerts its effects in SH-SY5Y cells.
Conclusions: Our study shows the ability of this pyrazolo-pyrimidine Src inhibitor in reducing the growth and the
invasiveness of human NB cells, suggesting a promising role as novel drug in the treatment of neuroblastoma.
Background
Neuroblastoma (NB) is the most common extracranial
pediatric solid tumour. It accounts for more than 7% of
malignancies in patients younger than 15 years and
around 15% of all paediatric oncologic deaths. NB origi-
nates from neural crest precursor cells as the results of
genetic alterations occurring in neural crest cells that
affect the normal developmental program [1,2]. NB may
present with a broad spectrum of clinical behaviour and
may have various prognosis depending on the assign-
ment to a risk group. However, about half of patients
present with evidence of metastasis and the majority of
tumors usually undergo rapid progression with a fatal
outcome. Although an aggressive and intensive multi-
modality approach (surgery, cytotoxic chemotherapy,
radio-metabolic treatment) has produced some improve-
ments in the overall cure rate of these patients, the
treatment strategies are still far from satisfaction [1,2].
Thus, innovative drugs are needed to develop novel
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of NB patients.
Several studies have identified the protein tyrosine
kinases (TKs) as targets for cancer therapy, since
enhancement of TK activity has been correlated with
cancer and other proliferative diseases [3]. For this rea-
son, many TK inhibitors (TKIs) have been tested for
their in vitro and in vivo anticancer activity [4], and
some of them have been approved in clinical trials or
are in clinical use [5,6]. A subclass of TKIs with strong
antiproliferative activity is represented by the inhibitors
of Src-family tyrosine kinases (SFK), a group of non-
receptor TKs involved in cancer development and inva-
sivity [7,8]. Src can stimulate cell proliferation, migration
and invasion as well as angiogenesis [9]. Moreover,
recent studies have suggested that Src may be impli-
cated in the development of drug resistance [10]. Over-
expression or aberrant activation of Src has been
detected in a variety of human cancers [11], including
NB [12,13], thus representing an attractive target for
therapeutic strategies against this tumour.
In the last years a series of novel pyrazolopyrimidine
derivatives synthesized in our laboratory have been
f o u n dt ob ea b l et oi n h i b i tS r cp h o s p h o r y l a t i o na n dt o
exert a potent antiproliferative action on different
human carcinoma cells, including A431 (epidermoid)
and 8701-BC (breast cancer) cell lines overexpressing
Src. Moreover the compounds reduce proliferation,
migratory ability and adhesive capacity of the invasive
prostate carcinoma cell line PC3 and inhibit the growth
of various human thyroid cancer cell lines. Some terms
of the pyrazolo-pyrimidine series showed antiprolifera-
tive activity on human osteogenic sarcoma (SaOS-2)
cells, reducing bone resorption when used to treat
mouse osteoclast and importantly decreased the volume
of human SaOS-2 xenograft tumour model in nude
mice [14-19]. Very recently we also showed that the
compounds are able to greatly reduce the growth rate of
medulloblastoma cells by decreasing Src phosphoryla-
tion and to inhibit tumour growth in vivo in a medullo-
blastoma mouse model [20].
In this work, we describe for the first time that micro-
molar concentration of pyrazolopyrimidine derivatives
reduce SH-SY5Y human neuroblastoma cells survival
and invasion, suggesting a potential role as novel drugs
in neuro-oncology.
Methods
Drugs
SI 34 and SI 35 were synthesized as previously described
[14,15]. SI 83 was synthesized in a similar way, but per-
forming the last step with meta-chloro-aniline in ethanol
at reflux [16]. Stock solutions of each compound were
prepared in dimethylsulfoxide (DMSO) at 50 mM,
stored in aliquots at -20°C and diluted in culture media
to the desired concentration just prior to use. The maxi-
mal concentration of DMSO utilized in this study
(0.02% in culture media, corresponding to the concen-
trations in 10 μM dilution of SI compounds) served as
vehicle controls. In comparison with untreated cultures,
DMSO 0.02% (1:5000 dilution) did not exert any signifi-
cant influence on any parameters analyzed in this study
(data not shown).
Cell culture, proliferation assays and cytotoxicity study
Experiments were carried out using two different human
peripheral nervous system (PNS) tumour cell lines, the
CHP100 human neuroepithelioma (NE) and the SH-
SY5Y human neuroblastoma (NB) culture [21,13] that
were grown as described [22,23]. To determine cell pro-
liferation, the cultures were seeded onto 6-well plates
(100×10
3 cells/well) for cell count or 96-well plates
(5×10
3 cells/well) for MTT assay. On the next day, the
growth medium was replaced with fresh medium
(untreated cultures) or with medium containing the pyr-
azolopyrimidine derivatives ranging from 1 to 10 μM.
Then, the cell growth was evaluated spectrophotometri-
cally (MTT test) or by cells counted after 24, 48 and 72
hour incubation [19].
Cytotoxicity was assessed by the trypan blue dye
exclusion test [22]. All reagents were from Sigma-
Aldrich (Milan, Italy).
Cytofluorimetric analysis
Analysis of DNA content was performed for the evalua-
tion of the cell cycle. 150×10
3 SH-SY5Y cells were pla-
ted in 35 mm dishes and treated the next day with SI
34 (1 and 10 μM) for 24-72 h. After stimulation, SH-
SY5Y cells were collected by trypsinization and centri-
fuged for 5 min at 200 g. Then, the cells were fixed in
cold 70% ethanol at 4°C for 2 hours, resuspended in 500
μl of staining solution (40 μg/ml propidium iodide and
500 μg/ml RNase A in PBS; all from Sigma) for 30 min
at 37°C and analyzed by flow cytometry.
Annexin V staining was performed according to the
kit manufacturer’s instructions (BD Biosciences, Milan,
Italy) to detect the apoptosis. Briefly, the cells were
detached by trypsin, washed with cold PBS, and sus-
pended in 1× binding buffer at a concentration of 1×10
6
cells/ml. Hundred microliters of the suspension were
transferred to a 5 ml culture tube and 5 μlF I T C
Annexin V were added. The samples were gently vor-
texed and incubated for 15 min at 25°C in the darkness.
Finally, 400 μl of 1× binding buffer were added to each
tube and the samples were analyzed by flow cytometry
within 1 hour. A FACSCalibur (BD Biosciences) flow
cytometer was used and the analysis was performed
with FlowJo software (BD Biosciences). Cultures treated
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positive control, both in cell cycle analysis and apoptosis
detection. Three sets of 10000 events were collected for
each condition.
Analysis of nuclear morphology by fluorescence
microscopy
SH-SY5Y cells were plated on glass coverslips and trea-
ted with 1-10 μM SI 34 for 24-72 hours. Then, the cul-
tures were fixed with 2% paraformaldehyde for 20 min
at 37°C and stained with 1 μg/ml of the DNA-binding
fluorochrome Hoechst 33258 (Bio-rad Laboratories,
Milan, Italy). Finally, the cells were observed with a
Nikon Diaphot fluorescence microscopy [24].
Caspase-3 activity assay
At the end of the SI 34 incubation (1 and 10 μM; 24-72
hours), SH-SY5Y cells were harvested and lysed in ice-
cold lysis buffer (50 mM HEPES, pH 7.4, 150 mM NaCl,
5 mM MgCl2, 5 mM EDTA, 0.1% 3[(3-cholamidopropyl)
dimethylammonium]-1-propanesulfonate (CHAPS), 5
mM dithiothreitol, 10 μgm l
-1 pepstatin A, 10 μgm l
-1
leupeptin and 10 μgm l
-1 aprotinin). The fluorimetric
assay for caspase-3 activity was performed as follows
[23]. Cell suspensions were sonicated, centrifuged at
12000 g for 10 min at 4°C and protein concentration in
supernatants was determined by the DC protein assay
(Bio-Rad Laboratories). Cell supernatants were diluted
in assay buffer (100 mM HEPES, pH 7.4, 5 mM EDTA,
0.1% CHAPS, 5 mM dithiothreitol and 10% glycerol) to
a final concentration of 0.6 μgo fp r o t e i np e rμla n d
incubated in triplicate in a 96-well clear-bottom plate
with the fluorogenic substrate acetyl-Asp-Glu-Val-Asp-
7-amino-4-methylcoumarin (Ac-DEVD-AMC; 50 μM;
Bachem, Bubendorf, Switzerland). Production of fluores-
cent-free AMC, released by caspase-3 activity, was mon-
itored over 60 min at 37°C using a microplate
fluorometer (Victor
2 multilabel counter, Perkin-Elmer
Life Sciences; excitation, 355 nm; emission, 460 nm).
The specific contribution of caspase-3 activity was deter-
mined by preincubating parallel sample aliquots with the
caspase-3 preferring inhibitor acetyl-Asp-Glu-Val- Asp-
aldehyde (Ac-DEVD-CHO; 50 μM; Bachem) for 10 min
at 37°C before the addition of the caspase substrate; the
difference between the substrate cleavage activity in the
absence and presence of Ac-DEVD-CHO was regarded
as specific caspase-3 activity.
Western blot analysis
Total proteins were extracted from SH-SY5Y cells as
previously described [19]. Confluent cell cultures from
three 100 mm Petri dishes were collected and homoge-
nized in 1 ml of buffer containing 50 mM Tris-HCl, 150
mM NaCl, 1%Triton, 0.25% sodium deoxycholate, 10
mM sodium pyrophosphate, 1 mM NaF, 1 mM sodium
orthovanadate, 2 mM PMSF, 10 μg/ml leupeptin, and
10 μg/ml aprotinin (all from Sigma-Aldrich). The homo-
genate was centrifuged at 10000 g (4°C for 10 min), and
the supernatant containing the whole-cell lysate was
quantified spectrophotometrically using the Bradford
method. Twenty micrograms of proteins were loaded
onto a 7.5% SDS-polyacrylamide gel electrophoresis and
electrotransferred to a Hybond ECL-PVDF nitrocellulose
membrane (GE Healthcare, Milan, Italy). Membranes
were blocked with TTBS/milk (TBS, 1% Tween 20, and
5% non-fat dry milk) for 2 hours at room temperature
and incubated with the following primary antibodies: a
1:1500 dilution of both an anti-Cyclin D1 and an anti-
Cyclin E antibodies (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA), an anti-Src monoclonal antibody
diluted 1/100 or a polyclonal antibody anti-phospho-Src
(Cell Signaling Technology, Beverly, MA, USA; cat n.
2102 and 2101, respectively), a 1/2000 dilution of a
polyclonal antibody anti-ERK2 or 1/100 of a polyclonal
antibody anti-phospho-ERK (Santa Cruz Biotechnology
Inc.) and a mouse monoclonal anti-human beta-actin
antibody (Sigma-Aldrich) diluted 1:5000 in TTBS/milk.
After repeated TTBS washes, the membrane was incu-
bated with horseradish peroxidase-conjugated anti-
mouse or anti-rabbit antibody (Transduction Labora-
tories, Lexington, KY, USA) diluted 1:10000 in TTBS/
milk and the protein was visualized with an enhanced
chemiluminescence Western blot detection system (ECL
plus, GE Healthcare).
Cell adhesion and invasion assays
Experiments of cell adhesion were conducted in the
same condition used in the cell proliferation assay (see
above). At the end of the SI 34 incubation times, the
morphology of SH-SY5Y cultures was examined by a
Nikon Diaphot microscope. Then, the cells were
detached by gentle agitation, washed off with culture
media, collected and counted in Neubauer hemocyto-
metric chamber in presence of trypan blue dye to distin-
guish between live and dead cells in suspension. The
weakly adherent cells were expressed as percentage of
the total cells present in the well, after subtraction of
the percentage of dead cells from the full amount of
detached cells. The adhesive capacity on specific sub-
strates was assayed by seeding cells at 5×10
5 cells/cm
2
in a 96-well plate coated with 10 μg/ml of Matrigel or
Collagen I (Sigma-Aldrich). Thirty minutes after seed-
ing, adherent cells were fixed with cold methanol for 10
min, washed with phosphate-buffered saline (PBS) and
air-dried. Adherent cells were stained with 100 μlo f
0.5% crystal violet w/v for 15 min at room temperature.
Then cells were rinsed with PBS and lysed with 2%
sodium dodecyl sulphate (SDS) w/v, 0.05% sodium azide
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bance was measured at 595 nm in a Bio-Rad Multiscan
plate reader (Hercules, CA, USA).
Cell invasion experiments were performed with the
Matrigel Invasion Chambers constituted by 24 well
plates equipped with 8 mm pore size polycarbonate fil-
ters overcoated with matrigel (Corning Inc., New York,
NY, USA). SH-SY5Y cells (1×10
5) were seeded in RPMI
with 2% FCS in the upper compartment of each cham-
ber. Medium with 10% serum was added to the lower
compartment. SI 34 was added to the upper compart-
ment and, after 24, 48 and 72 hours, the cells which had
invaded to lower side of the Matrigel coated filter were
collected and counted in Neubauer hemocytometric
chamber.
Statistical analysis
Data were expressed as mean ± S.E.M. and statistically
evaluated for differences using one-way analysis of var-
iance (ANOVA), followed by Turkey-Kramer multiple
comparison test (GrafPAD Software for Science).
Results
Structures of pyrazolo[3,4-d]pyrimidines
The 4-amino substituted pyrazolo[3,4-d]pyrimidine ring
represents a very interesting scaffold for the synthesis of
molecules potentially endowed with antitumor activities;
this structure is in fact isoster with that of the purine
derivative adenine, present in ATP, the natural phos-
phorylating agent that binds TKs. In our series of deri-
vatives a phenyl ring directly linked with the C4 amino
function (anilino derivative SI 83), or spaced by a
methylene (benzylamino derivative SI 34) or an ethylene
(phenylethylamino derivative SI 35) unit afforded the
most active compounds, at least for the biological activ-
ities tested until now. Moreover the chlorophenylethyl
N1 side chain and the C6 methylthio group are funda-
mental to maintain both enzymatic and cell activities
[14-19]. Structures of SI 34, SI 35 and SI 83 are
reported in Figure 1.
Effects of SI derivates on neuroblastoma and
neuroepithelioma cell growth
First, we investigated the ability of the three SI derivates
tested in this study to inhibit the proliferation of both
SH-SY5Y and CHP100 cell lines. As shown in Figure 2,
although with different efficacy, all SI molecules reduced
cell growth rate in a time and concentration-dependent
manner. In particular, the strongest effect on SH-SY5Y
was obtained by SI 34 10 μM, reaching its peak of
reduction in cell proliferation after 72 hours of treat-
ment (75% growth reduction in the MTT test; P < 0.001
vs control; Figure 2A). Similar results were observed
using CHP100 cells in which 10 μM SI 34 reduced the
proliferation by 65% after 72 hours of incubation (P <
0.001 vs control; Figure 2A). A lower but still significant
antiproliferative effect was observed also after treatment
of both SH-SY5Y and CHP100 cells with SI 35 and SI
83 (Figure 2A).
The MTT data was confirmed by counting the cells in
a Neubauer hemocytometer chamber after treatment
with SI molecules. As in MTT experiments, the best
inhibitory effect on the proliferation of both SH-SY5Y
and CHP100 cell lines was obtained by 10 μMS I3 4
(Figure 2B): 72 hours of exposure determined a 94%
reduction in cell proliferation of SH-SY5Y (P< 0.001 vs
control) and of 71% of CHP100 cells (P <0 . 0 0 1vs con-
trol). Again, SI 35 and SI 83 were less effective in redu-
cing NBs cell proliferation (Figure 2B).
Seventy-two hours exposure to 25 μM concentrations,
SI 34, SI 35 and SI 83 killed all the cells (data not
s h o w n ) .O nt h ec o n t r a r y ,n os i g n i f i c a n te f f e c to nc e l l
growth was observed with concentrations lower than 1
μM or after shorter incubation times (data not shown).
Cytotoxic effects induced by SI molecules
To determine whether SI molecules have cytotoxic
effects, both SH-SY5Y and CHP100 cells were exposed
to different concentrations of SI 34, SI 35 and SI 83 (1-
10 μM) for 24-72 hours, and the cell death was evalu-
ated using the trypan blue dye exclusion assay. As pre-
sented in Figure 3, treatment of SH-SY5Y cells with SI
34 resulted in a significant increase in cell death, that
rise up to a 33% after 72 hours of incubation (P <0 . 0 0 1
vs control). The same trend, but with a low rate of cyto-
toxicity, was observed treating SH-SY5Y cells with SI 35
and SI 83, and similar results were obtained in CHP100
cells (data not shown). Since the proliferation and
Figure 1 Chemical structure of the pyrazolopyrimidine
derivatives used in this study.
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active molecule tested in this study, and that the
response of CHP100 cells mimicked the effects obtained
in SH-SY5Y cells, further studies were carried out test-
ing the action of SI 34 on SH-SY5Y cells only.
SI 34 induces apoptosis
To elucidate the type of cell death induced by the SI
molecules, several markers of apoptosis were evaluated.
W ef i r s tc h e c k e dt h ep r e s e n c eo fc h a n g e si nt h em o r -
phology of the nuclei by staining the cells with the
Hoechst 33258. Apoptotic nuclei were identified by the
fragmentation of the nucleus and condensation of
nuclear heterochromatin, being highly fluorescent. As
illustrated in Figure 4A, after exposure of SH-SY5Y cells
to SI 34 (1 and 10 μM) for 72 hours, evidence of apop-
totic nuclei was observed.
Apoptosis was also detected by flow cytometric analy-
sis using the Annexin V staining. As shown in Figure
4B, SI 34 10 μM promoted SH-SY5Y cells apoptosis
after an exposure of both 48 and 72 hours (28% and
44% of cells, respectively). These results were confirmed
by additional experiments aimed to study the cell cycle,
in which the fraction of cells in apoptosis was identified
as a sub-G0 hypodiploid population (Table 1).
Additional fluorimetric assays were then performed
to verify whether SI 34-mediated apoptosis was asso-
ciated with caspase-3 activation. A significant increase
of caspase-3 activity was observed after 48 and 72
hours of exposure of SH-SY5Y cells to SI 34 10 μM
(Figure 4C).
SI 34 arrests SH-SY5Y cell cycle in G0/G1 phase
decreasing the expression of cyclin D1
To better characterize the antiproliferative activity of SI
34, we examined the progression of cells trough the cell
cycle by flow cytometry analysis. Table 1 shows that
exposure to SI 34 (1-10 μM; from 24 to 72 hours)
arrested the SH-SY5Y cell growth in G0/G1 phase in a
time and concentration-dependent manner. In particu-
lar, the treatment caused a reduction in the G2/M and
S phases of the cell cycle that were abolished after 72
hours of incubation, together with a parallel increase in
sub G0 phase (Table 1).
Figure 2 SI derivatives inhibit SH-SY5Y and CHP100 cell growth. Both SH-SY5Y and CHP100 cells were exposed to increasing concentration
of SI 34 compounds for the indicated periods of time. Proliferation rate was assessed by MTT assay (A) and cell counting (B). Results of MTT test
are expressed as percentages of the values detected in untreated cells. Each value is the mean ± S.E.M. of at least three experiments performed
in eightplicate (MTT test) or in triplicate (cell counting). *, ** and ***P < 0.05, P < 0.01 and P < 0.001 vs control and SI 34 1 μM; °P < 0.05 vs SI 34
2.5 μM.
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cell division cycle and their frequent deregulations in
cancer. Cyclin D1 governs the transit through the G1
phase of the cell cycle and is amplified and/or over-
expressed in a relevant proportion of human cancers,
including NB [25]. In order to estimate the contribution
of cyclins in the mechanisms by which SI 34 blocks the
SH-SY5Y cell cycle at G0/G1 phase, we examined the
expression of cyclin D1 and E in SH-SY5Y cells treated
with SI 34 by western blot assays. As shown in Figure 5,
when the cultures were exposed to SI 34 10 μM, a time-
dependent decrease of the cyclin D1 expression was
observed with the maximal reduction detected after 72
h of treatment (P <0 . 0 5vs untreated cultures). These
data demonstrate that SI 34 is able to reduce the cyclin
D1 expression in SH-SY5Y cells, suggesting a correlation
between the reduction of this protein level, the cells
cycle arrest and the inhibition of cellular proliferation.
Cyclin E is another rate limiting regulator in G1 phase
of the cell cycle and its appropriate regulation is essen-
tial to drive the cells in S phase. Cyclin E appears in late
G1 and disappears in early S phase. Interestingly, no
modulation of the cyclin E expression by SI 34 was
observed (data not shown), strengthening the hypothesis
that the block of the cell cycles induced by SI 34 occurs
at the early G1 phase.
SI 34 inhibits Src-TK and ERK-phosphorylation
To better understand the mechanisms underlying the
antiproliferative effects induced by SI 34, the involve-
ment of some cellular pathways that are important for
cell proliferation and survival like Src and extracellular
receptor kinases (ERK) phosphorylation was investigated
by western blot assays. In normal conditions, the level
of Src-phosphorylation in SH-SY5Y cells is low. Thus,
to enhance Src phosphorylation the cells were stimu-
lated with 100 nM insulin for 30 minutes, obtaining an
increase of phosphorylated Src level compared to the
untreated cultures (Figure 6A and 6B). SH-SY5Y cells
stimulated with insulin were treated with SI 34 (10 μM;
30 min) and the levels of phosphorylated and non-phos-
phorylated Src were examined. As a result, Src-phos-
phorylation promoted in SH-SY5Y cells by insulin was
inhibited using 10 μMS I3 4( P < 0.05) while the basal
levels of Src were not affected (Figure 6A and 6B).
We next investigated the effects of SI 34 on the phos-
phorylation of ERK. The results reported in Figure 6C
and 6D revealed an early inhibition of ERK-phosphory-
lation in the SH-SY5Y cells incubated with the test
compound (P <0 . 0 5vs no treated cells), without any
effect on the content of non-phosphorylated protein.
SI 34 reduces SH-SY5Y adhesion and invasion
In parallel with the decrease in cell proliferation, we
observed that the presence of SI 34 determined a modi-
fication in cellular morphology. The cells acquired a
round shape morphology, associated with a marked
increase of susceptibility in their detachment (Figure
7A). After treatment or not with SI 34, the cells were
detached by gentle agitation and counted. The weakly
Figure 3 Cytotoxic effects induced by SI 34 on SH-SY5Y cells.
Cytotoxic effect induced by SI 34 (1-10 μM; 24-72 hours) was
evaluated in terms of cell death assessed by trypan blue staining
exclusion assay. Data, expressed as mean ± S.E.M., represent the
values obtained in three different sets of experiments made in
triplicate. ***P < 0.001 vs control and SI 34 1 μM; °P < 0.01 vs SI 34
2.5 μM.
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Page 6 of 12Figure 4 Evaluation of apoptosis induced by SI 34 on SH-SY5Y cells. (A) Morphological analysis of nuclear chromatin in SH-SY5Y cells
stained with the DNA-binding fluorochrome Hoechst 33258. Cells with morphological changes in the nuclei or condensed chromatin were
defined as apoptotic cells. Arrows point the intense nuclear fluorescence present in some cells exposed to both SI 34 (1 and 10 μM) or
etoposide (50 μM). Nuclei were visualized by fluorescence microscopy at a magnification of 200×. A representative experiment that was
replicated three times with similar results is shown. (B) Annexin V (FITC) staining assay. SH-SY5Y cells undergoing apoptosis were detected by
cytofluorimetric analysis as described in materials and methods. Values reported depicted the percentage of events within the gate FL1 used to
define AnV+ cells. The red line represents the untreated culture. The green and blue lines symbolize the cells incubated with SI 34 1 and 10 μM,
respectively. The brown curve embodies SH-SY5Y cells exposed to etoposide 50 μM as inducer of apoptosis. The FACS analysis shown is
representative of three different experiments. (C) Caspase-3 activity assay performed as described in the materials and methods. Results are
expressed as percentage of relative fluorescence units (RFU) per min per mg of protein detected in untreated cultures, which are arbitrarily
expressed as 100%. Each value represents the mean ± S.E.M of three sets of experiments performed in triplicate. **P < 0.01 vs respective control;
^P < 0.01 vs 48 hours SI 34 1 μM; °P < 0.05 vs 72 hours SI 34 1 μM.
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SY5Y cultures were treated for 72 h with 10 μMo ft h e
test compound (Figure 7B). Moreover SH-SY5Y cells
were treated for 24 and 48 h with increasing concentra-
t i o n so fS I3 4( 1 ,5a n d1 0μM) and then we evaluated
their adhesive capacity on two different physiologic sub-
strates, matrigel and collagen I (Figure 7C). The same
experimental protocol was executed with non-coated
surface. Results demonstrated an evident trend towards
a decrease in adhesive capacity of treated cells in pre-
sence of all substrates and at higher concentrations of
SI 34. In particular, after 48 h, the percentages of adher-
ent cells on matrigel were significantly lower in treated
cells than in non-treated cells for all concentrations of
SI 34 (-30%, -32%, -47% respectively; P < 0.001).
Further studies were focused on the effect of SI 34 on
the SH-SY5Y invasion capability. As shown in Figure 8,
treatment with 10 μM SI 34 for 24-72 hours reduced
the cell invasiveness in a time-dependent manner. The
mean number of migrated cells reached statistical signif-
icance after 48 and 72 hours incubation with 10 μMo f
SI 34 (- 20% and - 25% respectively; P < 0.05 vs control).
Discussion
Among the novel approaches currently tested against
refractory NB, a promising role is played by small mole-
cules with Src inhibitory activity. Indeed, high levels of
Src have been found both in specimens from NB, in
which correlate with the neuronal/neuroendocrine dif-
ferentiation, the clinical stage and prognosis, and in NB
cell lines such as the SH-SY5Y cells [12,13]. Consistent
with these findings, Imatinib, a Bcr-Abl inhibitor, and
Dasatinib, a multi-targeted (including Bcr-Abl and Src)
inhibitor, have shown growth inhibitory effects on NBs
both in in vitro and in vivo preclinical models [26-29].
Moreover, a phase II clinical trial of Imatinib in children
with neuroblastoma and other solid tumors is ongoing
[30]. During the past decade, many pyrazolo[3,4-d]pyri-
midine compounds have been described and reviewed in
the literature as selective inhibitors of Src family and as
anti-proliferative agents [31]. However, they have never
been tested so far against paediatric solid tumours. For
the first time, we describe the effects of pyrazolopyrimi-
dine derivatives on human NB cells. In this study we
tested three pyrazolo[3,4-d]pyrimidine derivatives that
have already demonstrated potent inhibition of Src
Table 1 Cell cycle analysis of SH-SY5Y cells treated with
SI 34
cycle phase control SI 34 1 μMS I 3 4 1 0 μM Etoposide 50 μM
24 hours treatment
Sub G0 0 0 0 20 ± 1.2 ***
G0/G1 72 ± 1.7 81 ± 2.6 83 ± 1.8 * 69 ± 1.4
S 9 ± 0.5 4 ± 0.3 * 3 ± 0.7 * 3 ± 0.2 *
G2/M 19 ± 0.7 15 ± 1.0 14 ± 0.9 8 ± 0.8 *
48 hours treatment
Sub G0 0 12 ± 1.1 * 24 ± 2.2 *** 44 ± 2.7 ***
G0/G1 74 ± 3.1 76 ± 3.5 70 ± 3.6 48 ± 2.6 *
S 8 ± 0.8 4 ± 0.5 * 2 ± 0.1 * 1 ± 0.1 **
G2/M 18 ± 1.1 8 ± 1.1 * 4 ± 0.1 ** 7 ± 0.3 *
72 hours treatment
Sub G0 0 42 ± 3.2 *** 45 ± 2.9 *** 80 ± 4.1 ***
G0/G1 73 ± 4.7 58 ± 3.2 * 55 ± 2.97 * 20 ± 1.4 ***
S 11 ± 1.0 0 *** 0 *** 0 ***
G2/M 16 ± 0.8 0 *** 0 *** 0 ***
Progression trough cell cycle was examined by flow cytometry analysis. Data
analysis show that SI 34 arrests cell cycle at G0/G1 phase and abolishes the S
and G2M phase. Etoposide 50 μM was used as a positive control for cell cycle
arrest. Results are represented as percentages of the total cell population and
are the mean ± S.E.M. of three independent experiments. *, ** and ***P <
0.05, P <0 . 0 1a n dP <0 . 0 0 1vs respective control.
Figure 5 Analysis of cyclin D1 expression in SH-SY5Y treated
with SI 34. (A) Immunoblot of SH-SY5Y cells exposed to 10 μMS I
34 for 6-72 hours: a representative of three separate experiments is
shown. (B) Quantification of cyclin D1 expression from blots in
panels A achieved with ImageJ software. Histogram shows the
results of the densitometric analysis of autoradiographic bands in
which the protein levels were normalized for b-actin (black bars for
the untreated cultures and white bars for the cells exposed to SI 34
10 μM for the indicated times). Levels are extrapolated as
percentages of the values detected in control cells, which are
arbitrarily assigned as 100%.
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Page 8 of 12activation and cell proliferation: SI 35 revealed anti-pro-
liferative activity toward human epidermoid carcinoma
A431 cells [15] and human prostatic cell line PC3 [17];
SI 34 and SI 35 inhibited the proliferation of human
medullary and follicular thyroid cancer cells [18,19]; SI
83 reduced the growth rate in human osteosarcoma
cells [16].
Our present results show that SI molecules, although
with different extents, inhibit the growth of both SH-
SY5Y human NB and CHP100 human NE cell lines in a
time and concentration-dependent manner. NB and NE
are two closely related tumors of PNS, ontogenetically
related but different in some biochemical markers and
clinical features [21]. The striking difference in sensitiv-
ity of NB and NE cells to SI molecules may reflect the
heterogeneity of the human PNS cell lines [21]. Further-
more, the small variations in the chemical structure of
the tested compounds might provoke the difference in
their intrinsic activity on the two cell lines. Furthermore,
SI 34, the compound with the strongest activity, induces
caspase-3 activation that in turn causes SH-SY5Y
apoptotic cell death. Apoptosis is a physiological process
regulating tissue homeostasis. During the normal foetal
and postnatal development of the nervous system, apop-
tosis may occur spontaneously, because of the physiolo-
gical neuronal differentiation and activity of the cells.
Moreover, there is evidence that increased expression of
caspases in NBs is associated with favourable biological
features and improved disease outcome [32]. For this
reason, the NB presenting in the first age may regress
spontaneously, determining a good prognosis [1,33]. On
the contrary, delayed activation of normal apoptotic
pathways might be an important mechanism promoting
tumor survival and growth. For this reason, apoptosis of
NB cells has become the goal of many studies using
novel therapeutics in preclinical models. Our data also
demonstrate that SI 34 determined SH-SY5Y cell cycle
arrest at the G0/G1 phase, paralleled by decreased levels
of cyclin D1, whose over-expression has been described
in many human malignancies with poor prognosis [25].
These results are in line with literature data that
described a role of Src kinases in the cell cycle
Figure 6 Src- and ERK-phosphorylation in SH-SY5Y treated with SI 34. (A) SH-SY5Y cells were stimulated with insulin (100 nM; 30 min) in
the presence or absence of SI 34 (10 μM; 30 min), and then western blotting analysis of Src and phospho-Src was performed. A Western blot,
representative of three independent experiments showing similar results, is presented. (C) A representative gel (out of three) showed the ERK
and phospho-ERK expression in presence or not of SI 34 is illustrated. (B and D) Densitometric analysis of immunoreactive bands corresponding
to the Src-phosphorylated and ERK phosphorylated forms from blots A and C are reported. Autoradiographic bands were quantified by ImageJ
software and normalized for b-actin levels. Data are reported as percentages of the values detected in untreated cultures.
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Page 9 of 12Figure 7 SI 34 decreases SH-SY5Y cell adhesion. (A) Changes of cellular morphology in SH-SY5Y cultures exposed to 10 μMS I3 4f o r7 2
hours. (B) Detached cells from cultures exposed (white bars) or not (black bars) to SI 34 were collected and counted as described in materials
and methods. The results are expressed as percentage of detached cells (subtracted the percentage of dead cells from the full amount of
detached cells) with respect to the total number of cells present in the well. Each value is the mean ± S.E.M. of 6 different sets of experiments
made in triplicate. ***P < 0.001 vs respective controls. (C) Adhesion assay performed by plating SH-SY5Y cells on two different physiological
substrates (Matrigel and collagen I) and on non-coated plastic surface for 30 min. Cells were treated with increasing concentrations of SI 34 (0, 1,
5, 10 μM) for 24 or 48 hours prior the adhesion assay. The values are expressed as mean percentage with respect to control (black bar) of at
least three different measurements (± S.E.M). *, ** and ***P < 0.05, P < 0.01 and P < 0.001 vs respective control.
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Page 10 of 12regulation, in particular for the progression through G2/
M phase [34]. It is known that also ERK activation plays
a role in maintaining the growth and the malignant phe-
notype of cancer cells. Of interest, there is accumulating
evidence that Src may be responsible for the ERK activa-
tion in several experimental models [35,36], as well as it
has been reported that attenuation of ERK pathway may
correlate with a decreased cyclin D1 activity in NB cells
[37]. In light of the evidence, our results indicate that
the reduced Src phosphorylation induced by SI 34 is
associated with a decrease of ERK phosphorylation that
in turn may reduce the amount of cyclin D1, arresting
the SH-SY5Y cell cycle in G0/G1 phase. A relationship
between ERK phosphorylation and apoptosis has been
recently reported in SH-SY5Y cells [38]. Increased
expression and/or activation of both Src and ERK sig-
nalling are also critical for tumour cell adhesion and
migration [9,39]. Accordingly, inhibition of these kinases
by SI 34 reduced the SH-SY5Y cell adhesion on various
substrates and invasiveness. In particular, as demon-
strated in a different cell model, SI compounds may
impair cell adhesiveness and migration through the inhi-
bition of kinases in focal adhesion complex [17]. Taken
together, these data suggest that SI 34 may be effective
even in the prevention of NB cancer cells dissemination
and metastases development. Indeed, treatment with Src
inhibitors currently in clinical trials for a wide range of
solid tumours could reduce the incidence of metastases
[9].
Conclusions
Our data demonstrate the ability of the novel pyrazolo
[3,4-d]pyrimidine compounds in reducing the growth,
adhesion and invasiveness of human neuroblastoma
cells in vitro, suggesting a promising role as novel drugs
in the treatment of neuroblastoma.
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